Evidence map›Paper›PMID 42015937›Full record

ArticleFrontiers in immunology2026

Genomic characterization of rabies virus glycoprotein co-expressing CD70 CAR-T cells during killing of glioma cells

Feng Ji, Kexing Gao, Xianchen Wu, Hao Lin

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Feng JiOffice of Research Platform Management, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
Kexing GaoOffice of Research Platform Management, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
Xianchen WuDepartment of General Surgery, Shuyang Zhongxing Hospital, Suqian, China.
Hao LinOffice of Research Platform Management, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chimeric antigen receptor T cell therapy has limited efficacy in the treatment of glioma due to the blood-brain barrier and T cell exhaustion. Enhancement with rabies virus glycoprotein (RVG29) has shown improved brain-related efficacy. Methods: In this study, we developed CD70R CAR-T cells by modifying anti-CD70 CAR-T cells with RVG29 and tested their tumor-killing ability Results: Transcriptomic profiling via RNA-seq revealed the activated signaling pathways in modified CD70R CAR-T cells. These cells displayed effective Conclusion: The RVG29 modification enhances CAR-T therapy for brain tumors and holds promise for treating glioma.

Indexed as

Brain NeoplasmsGliomaGlycoproteinsImmunotherapy, AdoptiveRabies virusReceptors, Chimeric AntigenT-LymphocytesViral ProteinsAnimalsCell Line, TumorCoculture TechniquesCytotoxicity, ImmunologicHumansPeptide FragmentsGlycoproteinsPeptide Fragmentsrabies virus glycoprotein peptideReceptors, Chimeric AntigenViral Proteinsblood–brain barrierCAR-TgliomaimmunotherapyRVG29

Identifiers

PMID42015937
PMCPMC13093881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.